Pasar al contenido principal

EL SILENCIAMIENTO GENICO DE TPC1 GENERA UN FENOTIPO DE RESISTENCIA A LA OBESIDAD

PID2023-149533NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDADE DE SANTIAGO DE COMPOSTELA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

LEAP2 acts in hepatocytes and at central level, alleviates steatosis and inflammation but resistance in obese and aging

  • Varela Miguéns, Marta
  • Quintela Vilariño, Carmen
  • Casado Masa, Sabela
  • Oliveira Diz, Tadeu de
  • Müller, Timo D.
  • Nogueiras Pozo, Rubén
  • Diéguez González, Carlos
  • Tovar Carro, Sulay A.
Scope. Global increase in obesity and metabolic syndrome has led to a marked rise in comorbidities, with liver disease emerging as a major concern. Metabolic dysfunction-associated fatty liver disease (MAFLD) affects over 30% of the population, making it the most prevalent liver disorder worldwide. Hepatic steatosis, hallmark of MAFLD, can progress to inflammation, fibrosis, steatohepatitis, and cirrhosis. Despite advances in elucidating its mechanisms, no effective pharmacological therapy exists to reverse disease progression. Ghrelin signaling axis has been implicated in energy and lipid homeostasis, and the recent identification of liver-expressed antimicrobial peptide 2 (LEAP2) as an endogenous ghrelin receptor antagonist and inverse agonist has generated interest in its potential role in liver metabolism. The primary objective of this study was to evaluate LEAP2 on hepatocyte lipid metabolism and determine its capacity to prevent diet- and age-induced steatosis in vivo. Methods and results. We investigated LEAP2 actions on hepatocyte lipid metabolism using human and mouse hepatocyte cultures, also we did in vivo studies in mice with chronic central LEAP2 administration in models of diet-induced and age-related steatosis. LEAP2 inhibited lipid accumulation in hepatocytes and reduced hepatic lipid deposition in mice fed a standard diet. However, LEAP2 did not prevent high-fat diet–induced steatosis in young mice although it attenuated hepatic inflammation. In aged animals, LEAP2 failed to suppress age-associated inflammation and steatosis. Conclusion. LEAP2 has been identified as a novel regulator of hepatic lipid metabolism with the potential to counteract inflammation-associated steatosis, although its effects on age-related steatosis appear limited. Targeting the LEAP2–ghrelin axis may represent a promising therapeutic strategy; however, further studies are required to determine its efficacy in diet-induced hepatic disease.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Hypothalamus-liver talks: whispers in the language of metabolism

  • Ferreira, Vitor
  • Fernández González, Iara
  • Vattathara, Jane Jose
  • Rodríguez Díaz, Amanda
  • Fernández Sanmartín, Paola
  • Diéguez González, Carlos
Closely associated with the exponential increase of obesity and sedentary life, liver-related disorders are a major global health concern. Recent data suggest that the global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) among adults is of 32% and 5.1% for alcohol-related liver disease, with hepatic disorders contributing to 4% of global mortality, accounting for approximately 2 million deaths annually. Over the past two decades, the hypothalamus has emerged as a central hub in regulating whole body metabolic and energy homeostasis. Nevertheless, the interactome between the hypothalamus and the liver in the progression of liver metabolic dysfunctions, as well as its potential as a therapeutic target, remains poorly understood. In this review, we provide a comprehensive overview of the current knowledge regarding the hypothalamus-liver crosstalk, with a particular emphasis on the mechanisms underlying it. We explore how signals transmitted by different hormones can modulate these interactions, shedding light on their functional implications for hepatic regulation and systemic homeostasis through central signals.
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Hypothalamic GHRH

  • Diéguez González, Carlos
  • López Pérez, Miguel A.
  • Casanueva Freijo, Felipe
Despite initial discovery in pancreatic tumors, GHRH is a 44-amino acid peptide primarily expressed in the hypothalamus. Recent RNA sequencing clarifies GHRH expression: predominantly hypothalamic in humans, with some basal ganglia presence, while extending to additional central nervous system (CNS) regions in other species. GHRH binds to its G-protein coupled receptor (GHRHR) in the arcuate (ARC), ventromedial (VMH), and periventricular (PeN) nuclei of the hypothalamus to exert its effects. Notably, the highest non-brain expression is found in somatotroph cells of the pituitary, directly targeting growth hormone (GH) production. GHRH is the primary regulator of pulsatile GH secretion, counteracted by somatostatin. While early models proposed alternating GHRH/somatostatin bursts, others implicate somatostatin as the primary regulator of GH pulse timing. These models fail to fully explain species and gender differences, particularly regarding nutritional status. The discovery of ghrelin, acting via GHS-R1a on GHRH neurons, significantly advanced understanding of GH regulation. Ghrelin interacts intricately with GHRH, modulating its expression and neuronal activity. Ghrelin also exerts GHRH-independent GH stimulation and synergizes with GHRH. The crucial role of GHRH in GH regulation is demonstrated by its key involvement in the action of other GH regulators, such as leptin, neuropeptide Y (NPY), and orexins. However, these interactions have also revealed that the physiological effects of GHRH extend far beyond its canonical role as a GH secretagogue. In this context, GHRH is thought to be a key regulator of the sleep-wake cycle and may be involved in whole-body energy homeostasis. The objective of this review is to summarize the current knowledge on GHRH and to discuss the potential pleiotropic effect of this hypothalamic neuropeptide, far beyond its classical action as regulator of the somatotroph axis.